Lehman & Derafelo Financial Resources’s Sarepta Therapeutics SRPT Stock Holding History

Lehman & Derafelo Financial Resources’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,060	Closed	-$559K	–	180
2022 Q3	$559K	Sell	5,060 -75	-1%	-$7.56K	0.18%	53
2022 Q2	$385K	Buy	+5,135	New	+$378K	0.12%	68
2021 Q3	–	Sell	-12,517	Closed	-$973K	–	221
2021 Q2	$973K	Buy	12,517 +1,000	+9%	+$75.8K	0.27%	51
2021 Q1	$858K	Buy	11,517 +1,575	+16%	+$145K	0.24%	51
2020 Q4	$1.7M	Sell	9,942 -239	-2%	-$35.4K	0.51%	35
2020 Q3	$1.43M	Sell	10,181 -261	-2%	-$39.7K	0.46%	38
2020 Q2	$1.67M	Sell	10,442 -1,000	-9%	-$136K	0.58%	35
2020 Q1	$1.12M	Sell	11,442 -3,300	-22%	-$377K	0.47%	37
2019 Q4	$1.9M	Hold	14,742	–	–	0.68%	31
2019 Q3	$1.11M	Buy	14,742 +7,300	+98%	+$862K	0.42%	41
2019 Q2	$1.12M	Hold	7,442	–	–	0.46%	39
2019 Q1	$887K	Hold	7,442	–	–	0.38%	42
2018 Q4	$812K	Buy	+7,442	New	+$931K	0.4%	38

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lehman & Derafelo Financial Resources's SRPT Position: Q4 2022 in Review

Lehman & Derafelo Financial Resources sold out of Sarepta Therapeutics (SRPT) in Q4 2022, closing a stake of 5,060 shares — an estimated $559K sold.

Lehman & Derafelo Financial Resources first reported a position in SRPT in Q4 2018 and held it in 13 quarters. The position peaked at $1.9M in Q4 2019. 411 funds tracked by Wall St. Rank hold SRPT as of Q4 2022.

Lehman & Derafelo Financial Resources reported no remaining Sarepta Therapeutics position as of Q4 2022 after selling out during the quarter.
Lehman & Derafelo Financial Resources sold 5,060 Sarepta Therapeutics shares in Q4 2022, an estimated $559K.
Lehman & Derafelo Financial Resources first reported a position in Sarepta Therapeutics in Q4 2018 and held it in 13 quarters.
Lehman & Derafelo Financial Resources's Sarepta Therapeutics position peaked at $1.9M in Q4 2019.
411 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2022.

Based on Lehman & Derafelo Financial Resources's 13F filing for Q4 2022, filed 20 Jan 2023.